Drug or technology

Drug Therapy, Combination

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · JOURNAL ARTICLE

Pridinol treatment in cervical dystonia: improvement of non-motor symptoms.

Annals of Medicine

Non-interventional pilot study in 20 patients without a control arm, reporting motor and pain improvements with pridinol added to botulinum toxin, but lacking comparative evidence and power to support clinical decision-making.

PreliminaryAlexander Baumann Drug Therapy, Combination Carl Alexander Gless

Reported

Sample size20

Follow-up duration12 weeks

TWSTRS part I motor scoresignificantly improved V1 to V3

JUN 8, 2026 · JOURNAL ARTICLE

A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from a Dutch societal perspective.

Journal of Medical Economics

Model-based cost-effectiveness analysis demonstrates mavacamten meets accepted Dutch societal willingness-to-pay thresholds using established Markov modeling methods and published trial data.

Important Confirmatory EvidenceDrug Therapy, Combination Carla L Zema Adrenergic Beta-antagonists

Reported

Incremental QALYs3.09

Incremental LYs3.17

Incremental discounted costs€49,388